AstraZeneca Pays US$200 M Upfront for Ionis’ Rare Disease Drug
By Lucy Haggerty
Pharma Deals Review: Vol 2021 Issue 12 (Table of Contents)
Published: 15 Dec-2021
DOI: 10.3833/pdr.v2021.i12.2650 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Building its rare disease presence, AstraZeneca has agreed to collaborate with Ionis Pharmaceuticals to develop and commercialise the latter’s Phase III antisense drug, eplontersen...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS